In those with HCV-related cirrhosis, 6-monthly AFP-triage is more likely to be considered cost-effective; indeed, willingness to pay would have to rise to around £65 000 per QALY before 6-monthly AFP+US becomes most likely to be considered cost-effective in this population. Here, AFP is linked to Cirrhosis.